Document is current
Any future updates will be listed below
-
Authors
Patel, Sandip P.
Cano-Linson, Eleanor
Chae, Young Kwang
Schokrpur, Shiruyeh https://orcid.org/0000-0001-9441-9547
Lao, Christopher D.
Powers, Benjamin C.
Victor, Adrienne I.
Onitilo, Adedayo A.
Shin, Sarah
Takebe, Naoko
Threlkel, Sara
McLeod, Christine M.
Chen, Helen X.
Sharon, Elad
Othus, Megan
Ryan, Christopher W.
Blanke, Charles D.
Kurzrock, Razelle
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828, CA180888 CA180819 U10CA180820 CA180821 CA233331 CA233320 CA180828)
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 26 December 2024
First Online: 24 January 2025
Competing interests
: Kurzrock has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, and OmniSeq, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Roche and NeoMed. She serves as an advisor to Soluventis. She receives speaker fees from Roche and also has equity in IDbyDNA, CureMatch, Inc., and Soluventis. Patel reports grants from Bristol-Myers Squibb, personal fees from Bristol-Myers Squibb, during the conduct of the study; grants from Eli Lilly, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery. Fate Therapeutics, Genocea, Iovance, personal fees from AstraZeneca, Illumina, Tempus, Novartis, outside the submitted work. Chae reports research grants from Abbvie, BMS, Biodesix, Lexent Bio, Freenome; Honoraria/Advisory Boards from Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Guardant Health, Boehringer Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, and Takeda. During conduct of the trial, Sharon was a full-time employee of the National Cancer Institute (NCI), an arm of the United States government. He reports participation on Advisory Board for Mallinckrodt Pharmaceuticals. Othus reports consulting fees from Merck and Biosight. She serves participant on a Data Safety Monitoring Board or Advisory Board for BMS (Celgene), Grifols, and Glycomimetics. Lao reports research funding during this period from BMS, Genentech, and Dynavax. Ryan reported research support to institution from Bristol-Myers Squibb, Daiichi Sankyo Company, Genentech, Deciphera Pharmaceuticals, Exelixis, Karyopharm Therapeutics, Merck, Pfizer, Xynomic, PTC Therapeutics, NiKang Therapeutics, Shasqi, PF Argentum IP Holdings LLC, Novartis, Rain Therapeutics, IO Biotech, Seagen, Boehringer Ingelheim, and ALX Oncology. He reports providing expert testimony for Pfizer, GlaxoSmithKline, and Boehringer Ingelheim. Schokrpur reports consulting/advisory board fees from OncoHost. Blanke, Chen, Powers, Victor, Shin, Onitilo, and Takebe have no COI disclosures to report; McLeod, Cano-Linson, and Thelkel have no COI disclosures to report. The NCI negotiated a collaborative research and development agreement (CRADA) with Bristol-Myers Squibb to provide nivolumab and ipilimumab for this clinical trial.
